TIDES Oligonucleotide & Peptide Therapeutics

The TIDES Asia: Oligonucleotide & Peptide Therapeutics 2026 conference is Asia’s premier biopharmaceutical event dedicated to advancing the discovery, development, and commercialisation of next-generation modalities including oligonucleotides, peptides, mRNA therapeutics, and genome editing. Slated for 24–26 February 2026, the summit will take place at the Grand Nikko Tokyo Daiba in Tokyo, Japan and is designed to bring together scientists, engineers, industry decision-makers and innovators from across the Asia-Pacific and global markets to share cutting-edge strategies across discovery, development, chemistry, manufacturing and controls (CMC), and translational research.

Participants will have access to a comprehensive programme featuring expert keynotes, pre-conference workshops, scientific tracks, poster presentations and networking opportunities. Content spans advanced CMC strategies for oligonucleotide and peptide drugs, regulatory and manufacturing innovations, clinical development case studies, and novel approaches in mRNA and genome editing. The event facilitates cross-disciplinary exchange and collaborative innovation that accelerates therapeutic breakthroughs from research to real-world impact.